HistCite - [title] Word list:

Ranked [title] Word list

Mon Aug 28 13:00:22 2006

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,
essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al.
CANCER CELL 7 (4): 387-397 APR 2005
and the citing papers

stopwords, and 2-character and smaller words are excluded, Word count: 1426, All words count: 2092
Grand TLCS: 619, Grand TGCS: 834

View: Overview

Sorted by number of publications (Pubs).

Page 1 of 3: [ 1 2 3 ]

#	Word	Pubs	TLCS	TGCS
1	JAK	68	504	607
2	MUTATION	60	514	623
3	MYELOPROLIFERATIVE	47	200	270
4	V617F	44	245	331
5	DISORDERS	43	198	267
6	VERA	26	250	269
7	POLYCYTHEMIA	24	239	248
8	CHRONIC	23	98	122
9	MYELOFIBROSIS	21	185	198
10	MYELOID	19	201	242
11	ESSENTIAL	17	212	239
12	KINASE	17	246	294
13	PATIENTS	17	30	44
14	THROMBOCYTHEMIA	14	177	188
15	TYROSINE	13	235	281
16	CLINICAL	12	56	84
17	MOLECULAR	11	22	33
18	DIAGNOSIS	10	17	30
19	ACTIVATION	9	25	31
20	ACUTE	9	46	70
21	IDIOPATHIC	9	7	8
22	LEUKEMIA	9	43	60
23	METAPLASIA	9	170	178
24	PATHOGENESIS	9	14	22
25	ANALYSIS	8	13	18
26	IMPLICATIONS	8	34	60
27	ACTIVATING	7	217	242
28	BONE	7	7	8
29	MARROW	7	7	8
30	THROMBOSIS	7	7	9
#	Word	Pubs	TLCS	TGCS
31	ASSOCIATED	6	7	8
32	CELLS	6	7	7
33	EXPRESSION	6	32	40
34	KINASES	6	8	31
35	NEW	6	3	7
36	STAT	6	2	3
37	STATUS	6	38	56
38	TREATMENT	6	1	5
39	ACQUIRED	5	55	64
40	DISEASES	5	1	1
41	FEATURES	5	5	7
42	JAK2V617F	5	42	55
43	MALIGNANCIES	5	9	29
44	MANAGEMENT	5	0	2
45	ROLE	5	2	3
46	SYNDROME	5	0	1
47	ATYPICAL	4	47	70
48	BASIS	4	10	12
49	BUDD-CHIARI	4	0	1
50	CLASSIC	4	8	12
51	CLASSIFICATION	4	18	28
52	CLONAL	4	2	2
53	DETECTION	4	6	7
54	ERYTHROID	4	5	5
55	ERYTHROPOIETIN	4	0	3
56	GENE	4	12	23
57	INSIGHTS	4	3	8
58	JANUS	4	10	17
59	LONG-TERM	4	20	27
60	MYELODYSPLASTIC	4	47	72
#	Word	Pubs	TLCS	TGCS
61	POLYCYTHAEMIA	4	25	40
62	RECEPTOR	4	23	30
63	SIGNALING	4	9	19
64	SYNDROMES	4	47	72
65	THERAPY	4	0	0
66	UNCOMMON	4	12	14
67	BIOPSIES	3	3	4
68	CONSTITUTIVE	3	4	4
69	CONTROL	3	8	13
70	CORRELATION	3	3	3
71	DEVELOPMENT	3	0	0
72	DIAGNOSTIC	3	4	5
73	DISEASE	3	20	28
74	DOMAIN	3	2	2
75	FORMATION	3	21	28
76	GENETIC	3	0	5
77	HEMATOLOGICAL	3	1	2
78	HEMATOPOIETIC	3	2	2
79	HOMOZYGOUS	3	5	10
80	HUMAN	3	0	0
81	IDENTIFICATION	3	56	60
82	INCREASED	3	5	5
83	LEUKAEMIA	3	9	15
84	LEUKEMIAS	3	26	37
85	LYMPHOBLASTIC	3	19	32
86	MUTATIONS	3	4	5
87	OCCURS	3	19	25
88	PHOSPHORYLATION	3	0	4
89	PROTEIN	3	1	8
90	PRV	3	31	43
#	Word	Pubs	TLCS	TGCS
91	RARE	3	26	30
92	RESISTANCE	3	1	4
93	RESPONSE	3	1	2
94	SIGNAL	3	1	3
95	THROMBOCYTHAEMIA	3	35	51
96	TREPHINE	3	3	4
97	ABNORMALITIES	2	7	9
98	ACTIVATED	2	0	0
99	AKT	2	0	15
100	ALPHA	2	1	2
101	ASSAYS	2	2	3
102	ASSOCIATION	2	2	7
103	BLEEDING	2	3	5
104	CANCER	2	0	0
105	CANCERS	2	6	8
106	CAUSES	2	4	4
107	CELL	2	7	12
108	CHROMOSOMAL	2	4	6
109	CHROMOSOME-NEGATIVE	2	24	28
110	CLINICOPATHOLOGIC	2	0	0
111	CLINICOPATHOLOGICAL	2	0	1
112	CML	2	24	29
113	COEXPRESSION	2	2	2
114	COLONY	2	2	2
115	CORRELATES	2	20	27
116	CRITERIA	2	0	1
117	CURRENT	2	6	7
118	DERIVED	2	3	3
119	DIFFERENT	2	2	2
120	ETIOLOGY	2	2	3
#	Word	Pubs	TLCS	TGCS
121	EXPANSION	2	0	0
122	FACTOR	2	0	2
123	FACTORS	2	1	2
124	FIBROSIS	2	0	0
125	FLT	2	0	1
126	FOUND	2	26	32
127	FUNCTION	2	8	8
128	GATA	2	3	6
129	HEMATOPOIESIS	2	2	2
130	HETEROZYGOUS	2	5	5
131	HYDROXYUREA	2	0	1
132	IDENTIFIES	2	2	2
133	IMATINIB	2	1	3
134	IMPLICATION	2	1	2
135	INHIBITORS	2	1	5
136	LEADING	2	0	0
137	LEVELS	2	0	0
138	LOSS	2	8	8
139	MDS	2	3	7
140	MECHANISMS	2	3	8
141	MPD	2	22	30
142	MUTATIONAL	2	3	3
143	MYB	2	0	0
144	MYELOMONOCYTIC	2	21	27
145	NOVEL	2	0	1
146	NOVO	2	3	5
147	OCCURRENCE	2	50	57
148	ONCOGENIC	2	0	1
149	OVEREXPRESSION	2	21	28
150	PATHOLOGICAL	2	3	4
#	Word	Pubs	TLCS	TGCS
151	PCM1-JAK	2	3	7
152	PERSPECTIVES	2	0	0
153	PHENOTYPE	2	5	5
154	PHILADELPHIA	2	24	28
155	PLATELET	2	3	3
156	PLATELETS	2	0	0
157	POINT	2	0	0
158	PRESENCE	2	1	2
159	PROGNOSIS	2	0	1
160	PROGNOSTIC	2	20	27
161	PROSPECTIVE	2	15	25
162	QUANTITATIVE	2	3	3
163	RELATION	2	19	29
164	RELEVANCE	2	19	25
165	REPORT	2	17	25
166	RESEARCH	2	0	5
167	RISK	2	1	1
168	SCIENTIFIC	2	14	16
169	SCREENING	2	11	17
170	SECONDARY	2	10	15
171	SERIES	2	1	1
172	SINGLE	2	2	2
173	STEM	2	2	2
174	SUBSET	2	5	9
175	SUBTYPES	2	16	26
176	SYSTEM	2	0	1
177	TARGETS	2	0	12
178	TEST	2	5	7
179	THERAPEUTIC	2	10	12
180	THROMBOPOIETIN	2	6	11
#	Word	Pubs	TLCS	TGCS
181	TRANSDUCTION	2	1	3
182	TRANSFORMATION	2	8	9
183	TRANSLOCATION	2	3	7
184	ABDOMINAL	1	0	1
185	ABELSON-INDUCED	1	0	0
186	ABERRANT	1	0	0
187	ABL-NEGATIVE	1	1	3
188	ABSENCE	1	0	0
189	ABSENT	1	0	0
190	ACTIVATORS	1	0	0
191	ACTS	1	0	0
192	ADVANCES	1	6	7
193	AFFECT	1	6	11
194	AGNOGENIC	1	0	1
195	ALLELES	1	0	0
196	ALTERED	1	9	11
197	AML	1	1	1
198	ANALYSES	1	0	0
199	ANCILLARY	1	1	2
200	ANOVEL	1	0	0

Page 1 of 3: [ 1 2 3 ]